Disc Medicine Gains FDA Support for Bitopertin Trial
Company Announcements

Disc Medicine Gains FDA Support for Bitopertin Trial

Disc Medicine ( (IRON) ) just unveiled an announcement.

Disc Medicine, Inc. announced positive feedback from the FDA on its bitopertin treatment for erythropoietic protoporphyria (EPP), paving the way for the APOLLO clinical trial. The trial, set to start by mid-2025, will assess a 60 mg dose of bitopertin over six months, potentially leading to accelerated approval based on existing data. This aligns with the FDA on all proposed study parameters, offering a promising regulatory path forward for addressing this rare, debilitating disease.

See more insights into IRON stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyDisc Medicine reports Q3 EPS (89c), consensus ($1.05)
TipRanks Auto-Generated NewsdeskDisc Medicine Secures $200M Financing for Hematology Pipeline
TheFlyDisc Medicine secures $200M in non-dilutive debt financing
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App